Corporate
News release
TopHanoi, Vietnam – February 27 – Terumo Vietnam Medical Equipment (Terumo Vietnam) and Daiichi Sankyo Vietnam have signed a Memorandum of Understanding (MoU) to collaborate on advancing cardiovascular expertise in Vietnam.
The initiative aims to support healthcare professionals in updating their knowledge and skills in interventional cardiology.
Cardiovascular disease remains a significant health challenge in Vietnam, highlighting the need for ongoing education and training in diagnosis and intervention. Under the MoU, Terumo Vietnam and Daiichi Sankyo Vietnam plan to implement various initiatives, including scientific symposia, hands-on workshops, and continuous medical education (CME) sessions conducted both in person and online. Additionally, the partnership will focus on enhancing multidisciplinary team (MDT) workflows at comprehensive interventional cardiovascular centers and fostering collaboration between international and local medical institutions.
Terumo Vietnam specializes in medical devices, while Daiichi Sankyo Vietnam is known for its expertise in pharmaceutical therapies, particularly in antiplatelet treatments. Through this collaboration, both companies aim to support the management of acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI). The joint efforts will focus on enhancing PCI knowledge and techniques, strengthening coordination between departments such as emergency care (ER), intensive care units (ICU), and outpatient services, and improving post-PCI care and follow-up.
“This partnership reflects a commitment to supporting healthcare providers,” said Gaurav Chhillar, General Director of Terumo Vietnam Medical Equipment. “By working together, we hope to contribute to improved clinical decision-making and better treatment outcomes for cardiovascular patients.”
The MoU is part of broader efforts by both companies to support Vietnam’s healthcare system through education, mentorship, and professional development initiatives.
About Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. Operating in more than 20 countries, it draws upon over a century of scientific expertise and a robust pipeline of promising new medicines. With a team of 15,000 employees worldwide, Daiichi Sankyo is committed to developing innovative therapies and improving patient care.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.